Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Enliven Therapeutics, Inc.

Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights from clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. 

5AM Ventures

OrbiMed

Roche Venture Fund

Surveyor Capital

Boxer Capital

Janus Henderson Investors

Logos Capital

Cormorant Asset Management

Enliven Therapeutics

#DYK: Approximately 20% of people with CML switch therapy within the 1st year of treatment and up to 40% switch in the first 5 years of treatment. The majority of treatment switches occur early in the patient’s treatment course due to intolerance or lack and/or loss of molecular response. Join us on April 11th, to learn more about ELVN-001, our candidate for the treatment of CML: https://bit.ly/4cyFSP4

#DYK: Thanks to medical advancements, the number of patients living with #CML has more than doubled since the introduction of BCR-ABL TKIs, however, tolerability, safety, resistance and patient convenience concerns have become more prominent as patients can now expect to live on therapy for decades. Learn more: https://bit.ly/4afJ3cP 

We will be hosting a Virtual company event with KOLs on Thursday, 4/11, to discuss ELVN-001’s Phase 1a initial proof of concept data, the evolving treatment paradigm in #CML, and how ELVN-001 could fit into the CML landscape. Register here: https://bit.ly/4cyFSP4


#ICYMI: Yesterday we announced a $90M financing. We appreciate the support of our existing and new investors. This capital will help us continue to drive towards our goal of helping people with cancer to not only live longer, but live better. For more information, read the press release here: https://bit.ly/3TqPSkz 

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress. Learn more here: https://bit.ly/3Ve4whJ

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-11.34M -	-23.46M 106.96%	-18.97M 19.17%	-24.74M 30.44%	-37.66M 52.23%	-71.58M 90.07%
depreciation and amortization		33K -	45K 36.36%	115K 155.56%	215K 86.96%	297K 38.14%
deferred income tax		-215K -		-3.81M -		2.25M -
stock based compensation	555K -	899K 61.98%	130K 85.54%	1.92M 1,380%	3.19M 65.85%	12.91M 304.70%
change in working capital	1.24M -	673K 45.51%	583K 13.37%	3.57M 511.84%	438K 87.72%	1.40M 219.86%
accounts receivables
inventory
accounts payables	477K -	750K 57.23%	291K 61.20%	1.73M 495.88%	411K 76.30%	-2.25M 647.45%
other working capital	758K -	-77K 110.16%	292K 479.22%	1.83M 527.74%	27K 98.53%	3.65M 13,422.22%
other non cash items	770K -	196K 74.55%	9.68M 4,838.27%	3.81M 60.65%	1.74M 54.29%	-6.55M 476.05%
net cash provided by operating activities	-8.78M -	-21.88M 149.25%	-8.53M 61.01%	-19.13M 124.34%	-32.08M 67.64%	-61.27M 91.01%
investments in property plant and equipment		-140K -	-461K 229.29%	-191K 58.57%	-612K 220.42%	-149K 75.65%
acquisitions net					35M -
purchases of investments		-23.92M -	-64.20M 168.41%	-47.56M 25.93%	-35M 26.40%	-268.26M 666.47%
sales maturities of investments			47.50M -	45.94M 3.29%	41.88M 8.84%	120M 186.55%
other investing activites			16.70M -	1.62M 90.30%	-41.88M 2,685.06%	-1 100.00%
net cash used for investing activites		-24.06M -	-461K 98.08%	-191K 58.57%	-612K 220.42%	-148.41M 24,150.33%
debt repayment		-2.00M -
common stock issued		45.58M -	140K 99.69%	690K 392.86%	591K 14.35%	161.20M 27,175.97%
common stock repurchased				-226K -
dividends paid
other financing activites	6.49M -		130.37M -	-1.48M 101.14%	-2.39M 61.49%	73.08M 3,157.95%
net cash used provided by financing activities	6.49M -	43.58M 571.69%	130.51M 199.49%	-1.02M 100.78%	-1.80M 77.07%	234.29M 13,123.12%
effect of forex changes on cash		-88K -			74.20M -	54K 99.93%
net change in cash	-2.29M -	-2.45M 6.86%	121.52M 5,068.23%	-20.34M 116.74%	-34.49M 69.55%	24.66M 171.50%
cash at beginning of period	9.67M -	7.38M 23.67%	8.90M 20.51%	130.42M 1,366.04%	110.08M 15.60%	75.54M 31.38%
cash at end of period	7.38M -	4.94M 33.13%	130.42M 2,542.20%	110.08M 15.60%	75.59M 31.33%	100.19M 32.55%
operating cash flow	-8.78M -	-21.88M 149.25%	-8.53M 61.01%	-19.13M 124.34%	-32.08M 67.64%	-61.27M 91.01%
capital expenditure		-140K -	-461K 229.29%	-191K 58.57%	-612K 220.42%	-149K 75.65%
free cash flow	-8.78M -	-22.02M 150.85%	-8.99M 59.17%	-19.32M 114.96%	-32.69M 69.15%	-61.42M 87.89%

COM:ENLIVENTHERAPEUTICS

Enlivex Therapeutics Ltd.

Last Close

25.41

22/11 21:00

Market Cap

1.08B

Beta: -

Volume Today

254.16K

Avg: -

Preview